As reported in Biospace, xpovio (selinexor), a drug used to treat relapsed refractory multiple myeloma, received accelerated approval by the Food and Drug Administration this July.
About Multiple Myeloma
Multiple myeloma does not currently have a cure, and patients often find themselves running through the various available options, growing resistant to each new treatment as the disease continues to advance. This drug is for those who have already exhausted traditional treatments, with the tablet offered only to those who have already received extensive treatment of at least four prior methods, and a cancer that has exhibited resistance to such options.
Why is it important to identify the most deadly aspects of a disease, especially when there may be many different factors that make it dangerous? Share your thoughts with Patient Worthy!